Concepedia
Statistics
Publications
6
Citations
339
H-Index
Active since
2018
Affiliations
AstraZeneca (United Kingdom)(Current)
University of Cambridge
Cancer Research UK Cambridge Center
Harvard University
Cancer Research UK
Charles R. Dunlop is an author at AstraZeneca (United Kingdom) specializing in oncology, pharmacology, and medicine.
Publications per year
2018–2022
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine <i>In Vitro</i> and <i>In Vivo</i> to Induce Pancreatic Ductal Adenocarcinoma Regression
Yann Wallez, Charles R. Dunlop, Timothy Isaac Johnson et al. · Molecular Cancer Therapeutics · 2018 · 110 citations
Medicine, Oncology, Pharmacology +17
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models
Charles R. Dunlop, Yann Wallez, Timothy Isaac Johnson et al. · British Journal of Cancer · 2020 · 63 citations · Full text
p53 is regulated by aerobic glycolysis in cancer cells by the CtBP family of NADH-dependent transcriptional regulators
Charles N. Birts, Arindam Banerjee, Matthew Darley et al. · Science Signaling · 2020 · 54 citations · Full text
Life Sciences, Cell Biology, Molecular Genetics +15
Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine
Siang‐Boon Koh, Yann Wallez, Charles R. Dunlop et al. · Cancer Research · 2018 · 43 citations · Full text
Medicine, Oncology, Pharmacology +15
Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging
Nicole Strittmatter, Frances M. Richards, Alan Race et al. · Analytical Chemistry · 2022 · 39 citations · Full text
1–5 of 6